After taking an antidepressant for a few weeks, some people experience something. The worst of the darkness may lift around the edges, causing the depression to slightly lessen. However, there’s also something else: a slight dizziness, a word that refuses to come out, a walk into a room that ends with no idea why. Not everyone experiences it. However, it occurs frequently enough that scientists are beginning to seriously consider the possibility that medications meant to benefit the brain may also, in some ways, harm it.
In a nutshell, the answer is yes, occasionally, temporarily, for certain individuals. The longer response is much more convoluted, and it’s important to pay close attention to the thread because the subtleties are more important than the headline.
Among the most prescribed medications worldwide are SSRIs, or selective serotonin reuptake inhibitors, which include Zoloft, Prozac, and Lexapro. They are used by hundreds of millions of people, frequently for years at a time. For decades, researchers have been studying how they impact memory and cognition, but the results have been inconsistent, making it challenging to draw clear conclusions. According to a 2016 study that was published in a peer-reviewed journal, patients with depression or OCD who were just starting SSRI therapy gradually lost their ability to remember things. According to a large Israeli study that looked at over 71,000 adults over 60, those who had been prescribed antidepressants were more than three times more likely to develop dementia over the course of a four-year follow-up period than those who had not. These are figures that need to be taken seriously.
| Topic | Antidepressants and Their Effect on Memory and Cognitive Function |
|---|---|
| Drug Classes Under Study | SSRIs (Prozac, Zoloft, Lexapro, Citalopram), Tricyclic Antidepressants, SNRIs (Effexor) |
| Common Cognitive Side Effects | Brain fog, difficulty concentrating, memory lapses, confusion |
| Key Research Institutions | Rice University, University of Edinburgh, University College London, UCSF, NIH |
| Notable 2025 Study | Swedish national registry — 18,000+ dementia patients, observational study on SSRI use and cognitive decline (BMC Medicine) |
| Are Effects Permanent? | Generally not — most memory issues subside when medication is adjusted or stopped |
| Reference Website | PubMed Central — Do Antidepressants Increase the Risk of Dementia? |
However, this is the point at which the situation becomes truly complex and calls for a certain level of scientific caution. One major risk factor for cognitive decline is depression itself. According to certain meta-analyses, depression in later life is linked to about twice the risk of dementia. An individual in need of an antidepressant may already be on a neurological trajectory that no medication can completely reverse or create. Researchers continue to find that it is more difficult than it seems to distinguish between the effects of the medication and the illness it is intended to treat.
SSRI-using dementia patients experienced a faster rate of cognitive decline, according to a large 2025 Swedish study that looked at data from over 18,000 individuals with dementia enrolled in a national registry. With a large sample size and longitudinal data, it was a well-designed study that researchers take seriously. However, in response to the results, a number of neuroscientists cautioned against drawing the conclusion that SSRIs were the reason. According to Professor Tara Spires-Jones of the University of Edinburgh, individuals who required antidepressants might have had more aggressive underlying illnesses or that depression was impeding the course of their illnesses. More bluntly, Dr. Emma Anderson of University College London cautioned that there was a significant risk of confounding in the study design, meaning that what appeared to be a drug effect could actually be an illness effect. These are not refutations of the findings. They are frank explanations of how challenging it is to provide a clear response to this question.
Anticholinergic properties, a pharmacological feature of older tricyclic antidepressants and, to a lesser extent, some SSRIs like paroxetine, involve blocking acetylcholine, a neurotransmitter essential to memory and learning. This mechanism is the most obviously concerning. Cognitive processing slows down when the brain’s acetylcholine system is inhibited. This is reasonably well-established. The worry is that adding anticholinergic activity causes a sort of double pressure in a brain already struggling with the neurological burden of depression or early dementia. This risk is higher for older tricyclic antidepressants than for the majority of contemporary SSRIs, but this difference isn’t absolute because both individual sensitivity and prescription patterns are important.
Fortunately, there is more to this. According to a 2023 Rice University study that was published in Frontiers in Human Neuroscience, when antidepressants were effective, they seemed to improve overall memory function while also reducing negative memories in depressed individuals. This is a change in memory dynamics toward healthier function, according to Stephanie Leal, lead author of the study and an assistant professor of psychological sciences at Rice. The idea was that effectively treating depression seems to have cognitive benefits that can equal or exceed the cognitive costs, not that antidepressants always improve memory. Untreated depression shrinks the world, including the cognitive world.
It’s difficult to ignore how infrequently any of this is brought up in the typical prescription discussion. Sertraline’s FDA label admits that the drug may alter memory and make it difficult to focus, but most patients never read the fine print. After experiencing the brain fog effect for weeks, people tend to ignore it or cut back on their dosage covertly without telling anyone, believing it to be an uncomfortable side effect of their depression. It seems worthwhile to address this discrepancy between what research indicates and what patients are truly informed.
Overall, the available data points to the following: antidepressants can temporarily impair memory and cause cognitive haziness, especially when beginning treatment or changing dosages. These side effects are usually reversible. Certain SSRIs may hasten decline in individuals who already have dementia, but it is still unclear how depression affects this process. The cognitive picture is more nuanced in individuals with depression but no dementia, with some studies suggesting long-term risk and others suggesting cognitive benefit from effectively treated illness. Individual responses differ significantly, and different drug classes have different profiles. Whether any antidepressant directly causes long-term memory impairment in otherwise healthy adults is still unknown.
Practically speaking, this means that the discussion should take place between patients and prescribers in an open manner, with the research on the table rather than tucked away in a pamphlet that no one ever reads. Recall is important. The fact that the alternative is worse does not absolve the drugs that improve mood.